News Focus
News Focus
icon url

Whatsupp

03/24/19 12:58 PM

#8961 RE: XenaLives #8959

LOL, no peer review only paid consultants.
icon url

runncoach

03/24/19 12:58 PM

#8962 RE: XenaLives #8959

Yet none were viewed as Key Opinion Learders at the JP Morgan Conference as 2 on our SAB board were.

One of them, Martin Farlow was part of the team of researchers that abandoned M1 (one of the claims avxl points to but perhaps should no longer mention) for memory.
Apparently Jeffrey Cummings was part of that same study too. Maybe some have heard of him? Of course it was a controlled trial.

https://imgur.com/579PX0L

Highlights

MK-7622 is a positive allosteric modulator of the M1 receptor.


MK-7622 did not improve cognition or function in Alzheimer's disease patients.


MK-7622 increased cholinergically related side effects in Alzheimer's disease patients.


M1 positive allosteric modulation is not useful for treating Alzheimer's disease.